|
|
 |
|
Viewing report
|
|
|
|
Stakeholder Insight: Epilepsy - Neurologists remain loyal to brands in genericized market
Datamonitor, Dec 2010, Pages: 221
The epilepsy market has become increasingly competitive following the launch of Vimpat (lacosamide; UCB) in the US in May 2009 and patent expiries of the top four second-generation anticonvulsant drugs over 2008–09. However, the switching of stable epilepsy patients to a generic alternative remains controversial due to physicians’ concerns surrounding compromised seizure control.
Features and benefits
- Forecasts of diagnosed active epilepsy cases in the seven major markets based on a comprehensive epidemiological review.
- Estimated diagnosis rates, care pathway, and segmentation of epilepsy cases by partial onset and generalized seizures.
- In-depth analysis of treatment patterns and regimens prescribed for epilepsy by line of therapy.
- Analysis of five key brands, including established players and recent market entrants based upon physician perception and therapeutic role.
- Review of patient outcomes including prevalence of drug-resistant epilepsy.
Highlights
- Despite the launch of generic equivalents of four second generation anticonvulsants over 2008–09, branded anticonvulsants are the clear treatment of choice for neurologists when treating epilepsy patients. It is evident that neurologists are reluctant to switch epilepsy patients to generic products due to concerns over compromised seizure control.Neurologists initiate treatment of epilepsy with first generation anticonvulsants before progressing to, second generation products. However, throughout three lines of pharmacotherapy, fewer generalized epilepsy patients than partial onset epilepsy patients receives treatment with second generation anticonvulsants.
- Keppra is perceived as possessing the best overall efficacy and tolerability, and as such is positioned as the current gold-standard pharmacotherapy. This favorable perception is keeping with the drug’s market leading status in terms of 2009 sales revenues.
Your key questions answered
- How large is the population of patients with diagnosed active epilepsy? How do these patients progress through the care pathway?
- Which anticonvulsants are prescribed the most and what is their most common therapeutic role? How does this change at second- and third-line therapy?
- Which factors influence neurologists' prescribing decisions the most?
- How do neurologists perceive the efficacy and tolerability of Vimpat (lacosamide) - UCB's follow-on to its market leading epilepsy product, Keppra.
|
|
|
|
